#2
COMPANY OVERVIEW
Aerie Pharmaceuticals, Inc. (AERI) is a
clinical-stage pharmaceutical company
focused on developing treatments for
glaucoma, hypertension and other eye
diseases. The company has its sights set
on being a big player in the existing
ocular disease markets in U.S., Europe
and Japan which currently total $4.7
billion and are expected to grow to
more than $8 billion by 2023.
Aerie was founded in 2005, has a
market capitalization of approximately
$575 million and is currently selling at
just over $20 a share.